Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) are standard treatments for advanced solid cancers. Resistance to ICIs, both primary and secondary, poses challenges, with early mortality (EM) within 30-90 days indicating a lack of benefit. Prognostic factors for EM, including the lung immune prognostic index (LIPI), remain underexplored.

Methods

We performed a retrospective, observational study including patients affected by advanced solid tumors, treated with ICI as single agent or combined with other agents. Logistic regression models identified factors associated with EM and 90-day progression risks. A nomogram for predicting 90-day mortality was built and validated within an external cohort.

Results

In total, 637 patients received ICIs (single agent or in combinati

SUBMITTER: De Giglio A 

PROVIDER: S-EPMC11447166 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature